BioNotebook: Versartis VC funding, IPO filing; ANI 2013 earnings; Cardiome's ATM; Eleven's Phase III

Growth hormone developer Versartis announced a $55m Series E venture capital funding round on the morning of 18 February then filed for an $80m initial public offering after the stock market closed.

Redwood City, California-based Versartis is developing a once-monthly form of recombinant human growth hormone (rhGH) to treat growth hormone deficiency...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

06 Aug 2025

• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

31 Jul 2025

• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

25 Jul 2025

• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.